Further Debate on T3 + T4 Combination Therapy at ATA Meeting

The 89th annual meeting gets underway this week, with anaplastic thyroid cancer guidelines and combination T3 /T4 therapy among the highlights being discussed.
Medscape Medical News

Full Story →